Contravisory Investment Management Inc. Acquires Shares of 6,752 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Contravisory Investment Management Inc. bought a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 6,752 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Farallon Capital Management LLC increased its stake in Agios Pharmaceuticals by 1.1% during the 2nd quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock worth $243,822,000 after buying an additional 63,900 shares during the period. State Street Corp increased its position in shares of Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after acquiring an additional 216,484 shares during the last quarter. Erste Asset Management GmbH acquired a new position in shares of Agios Pharmaceuticals in the third quarter worth about $97,199,000. Geode Capital Management LLC boosted its holdings in Agios Pharmaceuticals by 0.5% in the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after purchasing an additional 6,101 shares during the last quarter. Finally, Marshall Wace LLP boosted its holdings in Agios Pharmaceuticals by 307.8% in the second quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock valued at $48,887,000 after purchasing an additional 855,739 shares during the last quarter.

Agios Pharmaceuticals Stock Down 4.4 %

Shares of NASDAQ AGIO opened at $31.82 on Friday. The stock has a market capitalization of $1.81 billion, a P/E ratio of 2.80 and a beta of 0.87. The firm’s 50-day moving average price is $45.25 and its two-hundred day moving average price is $45.13. Agios Pharmaceuticals, Inc. has a 52-week low of $20.96 and a 52-week high of $62.58.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the sale, the insider now directly owns 18,906 shares of the company’s stock, valued at $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.93% of the company’s stock.

Wall Street Analyst Weigh In

AGIO has been the topic of a number of recent analyst reports. Royal Bank of Canada upped their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Leerink Partners downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Leerink Partnrs cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $56.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.